Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer [SUBSTUDY OF 700216591]
Latest Information Update: 12 Feb 2024
At a glance
- Drugs Cyclophosphamide (Primary) ; Docetaxel (Primary) ; Epirubicin (Primary) ; Paclitaxel (Primary)
- Indications Carcinoma; Early breast cancer
- Focus Therapeutic Use
- Acronyms ADAPT; ADAPT HR+/HER2-
- 24 Oct 2023 Results (n=4491) assessing the impact of recurrence score, clinical-pathological factors, gene mutations and histology in early HR+/HER2- breast cancer, presented at the 48th European Society for Medical Oncology Congress.
- 01 Apr 2023 Results published in the Modern Pathology
- 23 Mar 2023 Planned End Date changed from 1 Sep 2024 to 1 Oct 2024.